- Home
- TMDX
as 11-14-2024 4:00pm EST
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ANDOVER |
| Market Cap: | 4.7B | IPO Year: | 2019 |
| Target Price: | $138.20 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $63.86 - $177.37 | Next Earning Date: | 10-28-2024 |
| Revenue: | $401,090,000 | Revenue Growth: | 109.09% |
| Revenue Growth (this year): | 83.25% | Revenue Growth (next year): | 26.27% |
Stock Insider Trading Activity of TransMedics Group Inc. (TMDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Khayal Tamer I | TMDX | Chief Commercial Officer | Nov 1 '24 | Sell | $82.64 | 1,083 | $89,499.12 | 20,843 | |
| Hassanein Waleed H | TMDX | President & CEO | Oct 15 '24 | Sell | $133.50 | 8,625 | $1,144,648.13 | 61,643 | |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Oct 1 '24 | Sell | $150.34 | 2,958 | $438,490.90 | 20,843 | |
| Hassanein Waleed H | TMDX | President & CEO | Sep 16 '24 | Sell | $153.84 | 8,625 | $1,323,209.86 | 61,643 | |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Sep 3 '24 | Sell | $161.28 | 2,960 | $472,403.54 | 20,843 | |
| Corcoran Nicholas | TMDX | See Remarks | Aug 27 '24 | Sell | $176.02 | 10,000 | $1,760,200.00 | 21,105 | |
| Hassanein Waleed H | TMDX | President & CEO | Aug 21 '24 | Sell | $173.02 | 45,000 | $7,795,600.00 | 61,643 |
Latest TransMedics Group Inc. News
TMDX Breaking Stock News: Dive into TMDX Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
TMDX: Raising target price to $96.00
Motley Fool
6 days ago
Down 52%, Is TransMedics Stock a Buy on the Dip?
Motley Fool
8 days ago
Why TransMedics Stock Plunged in October
Argus Research
9 days ago
TMDX: Lowering target price to $87.00
Motley Fool
11 days ago
1 Top Growth Stock Down 50% to Buy After Its Recent Pullback
Zacks
16 days ago
TransMedics (TMDX) Reports Q3 Earnings: What Key Metrics Have to Say
Simply Wall St.
16 days ago
TransMedics Group Third Quarter 2024 Earnings: Misses Expectations
PR Newswire
17 days ago
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Compare TMDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TMDX TransMedics Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.